{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:32:33Z","timestamp":1770323553905,"version":"3.49.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Melanoma is one of the great mimickers in pathology because it has diverse morphologies and can be mistaken for carcinoma or sarcoma. In most cases, immunochemistry is helpful in supporting the diagnosis and excluding other differentials. However, metastatic melanoma may lose immunohistochemical melanocytic markers and express nonmelanocytic lineage markers, which often poses a diagnostic dilemma and may be misdiagnosed as a poorly differentiated carcinoma or sarcoma. We report the case of a 52-year-old woman who had a history of recurrent melanoma on her right shoulder with axillary lymph node metastasis (BRAF V600K\u2013mutated melanoma) and right-side breast-invasive ductal carcinoma (stage pT1b N0sn). One year later, she presented with a left-sided chest wall mass and enlarging left axillary lymph nodes. Needle core biopsies were obtained from both lesions, and histologic examination showed a poorly differentiated tumor with pleomorphic\/anaplastic morphology and necrosis. The tumor cells were strongly immunoreactive for GATA-3 without expression of melanocytic markers (S100, Melan A, HMB45, SOX10, MITF, and tyrosinase). The history of melanoma prompted molecular analysis, and the lesion was found to harbor the BRAF V600K mutation, consistent with metastatic dedifferentiated melanoma. Recognition of metastatic dedifferentiated melanoma is important to avoid misdiagnosis of carcinoma, especially in patients with a previous history of carcinoma.<\/jats:p>","DOI":"10.1097\/dad.0000000000001322","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T19:01:04Z","timestamp":1545159664000},"page":"502-504","source":"Crossref","is-referenced-by-count":10,"title":["Dedifferentiated Melanoma With Expression of Cytokeratin and GATA3 in a Patient With History of Breast Carcinoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Ahmad","family":"Alkhasawneh","sequence":"first","affiliation":[{"name":"Department of Pathology, Immunology and Laboratory Medicine, College of Medicine\u2014Jacksonville, University of Florida, Jacksonville, FL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Nassri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine\u2014Jacksonville, University of Florida, Jacksonville, FL; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivy","family":"John","sequence":"additional","affiliation":[{"name":"Department of Pathology, UPMC Shadyside, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.jaad.2011.04.036","article-title":"The health burden and economic costs of cutaneous melanoma mortality by race\/ethnicity-United States, 2000 to 2006","volume":"65","author":"Ekwueme","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"R2-20230908","first-page":"591","article-title":"Vital signs: melanoma incidence and mortality trends and projections\u2014United States, 1982-2030","volume":"64","author":"Guy","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/107327480501200403","article-title":"Cutaneous melanoma: prognostic factors","volume":"12","author":"Homsi","year":"2005","journal-title":"Cancer Control."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jaad.2011.05.030","article-title":"Melanoma survival in the United States, 1992 to 2005","volume":"65","author":"Pollack","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PAS.0000000000000527","article-title":"Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated\/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker","volume":"40","author":"Agaimy","year":"2016","journal-title":"Am J Surg Pathol."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.humpath.2005.07.010","article-title":"Loss of S100 antigenicity in metastatic melanoma","volume":"36","author":"Aisner","year":"2005","journal-title":"Hum Pathol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0560.2007.00891.x","article-title":"Immunohistochemical characteristics of melanoma","volume":"35","author":"Ohsie","year":"2008","journal-title":"J Cutan Pathol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.oooo.2015.11.016","article-title":"Immunohistochemical expression of keratins 6, 7, 8, 14, 16, 18, 19, and MNF-116 pancytokeratin in primary and metastatic melanoma of the head and neck","volume":"121","author":"Safadi","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/cup.13122","article-title":"Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component","volume":"45","author":"Campbell","year":"2018","journal-title":"J Cutan Pathol."},{"issue":"suppl 10","key":"R12-20230908","doi-asserted-by":"crossref","first-page":"x271","DOI":"10.1093\/annonc\/mds357","article-title":"Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling","volume":"23","author":"Oien","year":"2012","journal-title":"Ann Oncol."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"853","DOI":"10.5858\/2009-0717-RAR.1","article-title":"Immunohistochemistry of melanocytic proliferations","volume":"135","author":"Prieto","year":"2011","journal-title":"Arch Pathol Lab Med."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13000-015-0431-9","article-title":"A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"10","author":"Uguen","year":"2015","journal-title":"Diagn Pathol."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/PAS.0000000000000398","article-title":"Sox10\u2014a marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors","volume":"39","author":"Miettinen","year":"2015","journal-title":"Am J Surg Pathol."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.humpath.2017.08.011","article-title":"Utility of Sox10 labeling in metastatic breast carcinomas","volume":"67","author":"Nelson","year":"2017","journal-title":"Hum Pathol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jasc.2016.12.002","article-title":"Utility and pitfalls of GATA3 immunocytochemistry for diagnosis of metastatic breast carcinoma and urothelial carcinoma on cytology specimens","volume":"6","author":"Leng","year":"2017","journal-title":"J Am Soc Cytopathol."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1309\/AJCP5UAFMSA9ZQBZ","article-title":"Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas","volume":"138","author":"Liu","year":"2012","journal-title":"Am J Clin Pathol."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/DAD.0000000000000306","article-title":"GATA3 expression in normal skin and in benign and malignant epidermal and cutaneous adnexal neoplasms","volume":"37","author":"Mertens","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am J Surg Pathol."},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jcp.55.2.88","article-title":"Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma","volume":"55","author":"Frkovic-Grazio","year":"2002","journal-title":"J Clin Pathol."},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1200\/JCO.2007.15.5986","article-title":"Prognostic significance of Nottingham histologic grade in invasive breast carcinoma","volume":"26","author":"Rakha","year":"2008","journal-title":"J Clin Oncol."},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.28306","article-title":"Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma","volume":"119","author":"Bucheit","year":"2013","journal-title":"Cancer."},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J Transl Med."},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/DAD.0000000000000404","article-title":"BRAF-V600 mutation heterogeneity in primary and metastatic melanoma: a study with pyrosequencing and immunohistochemistry","volume":"38","author":"Yaman","year":"2016","journal-title":"Am J Dermatopathol."},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CMR.0000000000000388","article-title":"Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma","volume":"27","author":"Li","year":"2017","journal-title":"Melanoma Res."},{"key":"R27-20230908","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res."},{"key":"R29-20230908","doi-asserted-by":"crossref","first-page":"e70826","DOI":"10.1371\/journal.pone.0070826","article-title":"Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing","volume":"8","author":"Boursault","year":"2013","journal-title":"PLoS One."},{"key":"R30-20230908","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer."},{"key":"R31-20230908","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun."},{"key":"R32-20230908","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-018-4767-1","article-title":"Mutational analysis of triple-negative breast cancers within the international breast cancer study group (IBCSG) trial 22-00","volume":"170","author":"Munzone","year":"2018","journal-title":"Breast Cancer Res Treat."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201907000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:00:36Z","timestamp":1694149236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201907000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001322","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}